ogarawo.wordpress.com
million Series A financing round, according to a U.S. Securitiesd and Exchange Commission filing. The Austin-baseds company is developing an inhalation-based drug delivery systenm and will use the fundds to continue development of its NanoCluster technolog in the dry powdertherapeutics Savara, which moved from Kansas last didn’t disclose its investors, but the SEC filing indicates they'vs attracted 13 backers. Savara was founded in 2007 with technologyh developed atthe . In late 2008, it move to the five months after Austin entrepreneufr Rob Neville was namedthe company’s chairman and CEO.
Nevillde previously was founder and CEO ofanother ATI-based company, That startupo was acquired in 2000 by Houston-based for $100 million abou t a year after it was founded. Savara’s pulmonargy — or via the lungs — drug deliveru product, initially developed in is based on nanotechnologyh and dry powders rather than conventional It plans to offer its platform to drug makers seeking alternative delivery methods and to develop itsown drugs. Last Savara garnered an undisclosed amount of financingg from a syndicate of 12angel investors, most based in Neville said. During 2008, Austin-area life sciences companie attracted $18.7 million in venture capital comparedwith $195.
1 milliomn in 2007, according to .
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment